IP Library Granted Patent US 7,897,382
Granted Patent B2
US 7,897,382 · App. 12/034,541 · Granted Mar 1, 2011

Transfection kinetics and structural promoters

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,897,382
App. No.
12/034,541
Granted
Mar 1, 2011
Kind
B2
Abstract

The invention features methods of analyzing the kinetics properties of transfection reactions. Also featured are methods for creating structural promoters which are effectively unregulated by enhancers and repressors. The structural promoters are significantly more active than the native promoter sequences upon which they are based.

Claims (41)

1. A composition comprising a supercoiled DNA comprising a promoter sequence annealed to a torsionally locked DNA oligonucleotide, wherein said promoter sequence is operably linked to a nucleic acid sequence.

2. A method for generating an open-promoter complex comprising:

(i) providing a purified plasmid in supercoiled form, the plasmid containing a sequence for expression;

(ii) creating a padlocked DNA oligonucleotide to generate an open-promoter complex for said sequence for expression.

3. A composition, comprising:

a purified plasmid DNA in supercoiled form, the construct containing a sequence for expression; and

a padlocked DNA oligonucleotide annealed to said construct, wherein the padlocked DNA oligonucleotide generates an open-promoter complex for said sequence for expression.

4. The composition of claim 1 , wherein the promoter sequence is an HCMV promoter sequence.

5. The composition of claim 1 , wherein the nucleic acid sequence encodes an RNA or a protein.

6. The composition of claim 1 , wherein the DNA oligonucleotide is annealed to the non-coding strand of the super-coiled DNA.

7. The composition of claim 1 , wherein the DNA oligonucleotide is base-paired with the promoter sequence beginning at sequences −1 to the transcription initiation site of the nucleic acid sequence.

8. The composition of claim 1 , wherein the DNA oligonucleotide is base-paired with the promoter sequence within a region of about −10 to about −70 from the transcription initiation site of the nucleic acid sequence.

9. The method of claim 2 , wherein the sequence for expression is operably linked to a promoter.

10. The method of claim 9 , wherein the padlocked DNA oligonucleotide is annealed to a TATA or CAT box within the promoter.

11. The method of claim 9 , wherein the padlocked DNA oligonucleotide is annealed to the non-coding strand of the supercoiled DNA.

12. The method of claim 9 , wherein the padlocked DNA oligonucleotide is annealed to the coding strand of the supercoiled DNA.

13. The method of claim 2 , wherein the sequence for expression is not operably linked to a promoter.

14. The method of claim 13 , wherein the sequence for expression contains an initiating ATG codon or is a dsRNA coding region.

15. The method of claim 14 , wherein the padlocked DNA oligonucleotide is annealed to the non-coding strand of the supercoiled DNA.

16. The method of claim 14 , wherein the padlocked DNA oligonucleotide is annealed to the coding strand of the supercoiled DNA.

17. The composition of claim 3 , wherein the sequence for expression is operably linked to a promoter.

18. The composition of claim 17 , wherein the padlocked DNA oligonucleotide is annealed to a TATA or CAT box within the promoter.

19. The composition of claim 17 , wherein the padlocked DNA oligonucleotide is annealed to the coding strand of the supercoiled DNA.

20. The composition of claim 17 , wherein the padlocked DNA oligonucleotide is annealed to the coding strand of the supercoiled DNA.

21. The composition of claim 3 wherein the sequence for expression is not operably linked to a promoter.

22. The composition of claim 21 , wherein the sequence for expression contains an initiating ATG codon or is a dsRNA coding region.

23. The composition of claim 22 , wherein the padlocked DNA oligonucleotide is annealed to the non-coding strand of the supercoiled DNA.

24. The composition of claim 22 , wherein the padlocked DNA oligonucleotide is annealed to the coding strand of the supercoiled DNA.

25. A method for producing a forced open promoter complex, wherein the forced open promoter complex promotes an increase in transcription of a nucleic acid sequence, the method comprising:

annealing a single stranded RNA oligonucleotide of 12 to 100 nucleotides to a supercoiled DNA comprising the nucleic acid sequence, wherein the RNA oligonucleotide anneals to the supercoiled DNA at a target sequence between nucleotides −1 and −45 of the promoter of the nucleic acid sequence and wherein the 5′ end of the RNA oligonucleotide anneals to an upstream end of the target sequence, wherein the 3′ end of the RNA oligonucleotide anneals to a downstream end of the target sequence, wherein the upstream and downstream ends of the target sequence comprise a contiguous sequence of the supercoiled DNA and wherein the annealed single stranded RNA oligonucleotide produces a forced open promoter complex.

26. The method of claim 25 , wherein the single stranded RNA oligonucleotide comprises an intervening connecter sequence that connects the 5′ end to the 3′ end that lacks complementarity with the supercoiled DNA.

27. The method of claim 25 , wherein the RNA oligonucleotide comprises at least 20 nucleotides.

28. The method of claim 25 , wherein the RNA oligonucleotide comprises at least 30 nucleotides.

29. The method of claim 26 , wherein the intervening connecting sequence comprises a sequence that is useful for targeting or transcriptional purposes.

30. The method of claim 29 , wherein the intervening connecting sequence comprises a sequence that promotes binding of a polymerase or a transcription factor.

31. The method of claim 30 , wherein said polymerase is an RNA polymerase.

32. The method of claim 25 , wherein the target sequence is a TATA or CAT box that is upstream from the transcription initiation site of the nucleic acid sequence.

33. The method of claim 25 , wherein annealing the RNA oligonucleotide to the supercoiled DNA promotes an increase in the expression of the nucleic acid sequence relative to the expression of nucleic acid sequence in a supercoiled DNA lacking an annealed RNA oligonucleotide.

34. The method of claim 25 , wherein the RNA oligonucleotide does not anneal downstream of the −1 position.

35. The method of claim 25 , wherein the RNA oligonucleotide is annealed to the non-coding strand of the supercoiled DNA.

36. The method of claim 25 , wherein the RNA oligonucleotide is annealed to the coding strand of the supercoiled DNA.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2009
From: NUCLEONICS, INC.
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 022386/0468 →
RELEASE OF SECURITY INTEREST Recorded Dec 5, 2008
From: NEW ENTERPRISE ASSOCIATES 10, LIMITED PARTNERSHIP; BURRILL LIFE SCIENCES CAPITAL FUND, L.P.; BURRILL INDIANA LIFE SCIENCES CAPITAL FUND, L.P.; OFCO CLUB IV; HEALTHCAP IV KB; HEALTHCAP IV, L.P.; HEALTHCAP IV BIS, L.P.; S.R. ONE, LIMITED; QUAKER BIOVENTURES, L.P.; QUAKER BIOVENTURES TOBACCO FUND, L.P.; POSCO BIOVENTURES I, L.P.
To: NUCLEONICS, INC.
Reel/Frame 021932/0001 →
SECURITY AGREEMENT Recorded Sep 29, 2008
From: NUCLEONICS, INC.
To: NEW ENTERPRISE ASSOCIATES 10, LIMITED PARTNERSHIP; S.R. ONE, LIMITED; OFCO CLUB IV; HEALTHCAP IV KB; HEALTHCAP IV, L.P.; HEALTHCAP IV BIS, L.P.; BURRILL LIFE SCIENCES CAPITAL FUND, L.P.; BURRILL INDIANA LIFE SCIENCES CAPITAL FUND, L.P.; QUAKER BIOVENTURES, L.P.; QUAKER BIOVENTURES TOBACCO FUND, L.P.; POSCO BIOVENTURES I, L.P.
Reel/Frame 021602/0423 →